StockpollyBeta
Get App
Delisting riskPopularity #4,594
IGC · AMEX · Biotechnology

IGC Pharma (IGC)

Develops an investigational oral THC-and-melatonin therapy for Alzheimer’s-dementia agitation.

$0.2785
After-hours close−0.00 (−1.03%)
At close$0.2814(+2.70%)

  1. IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure

    AccesswireEarnings

  2. IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout

    Accesswire

  3. IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign

    Accesswire

  4. IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow

    Accesswire

  5. IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company

    Accesswire

  6. IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow

    Accesswire

  7. IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis

    Accesswire

  8. Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts

    Accesswire

  9. IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis

    Accesswire

  10. IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment

    Accesswire

  11. IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference

    Accesswire

  12. IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase

    Accesswire

  13. IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion

    Accesswire

  14. IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia

    Accesswire

  15. IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout

    Accesswire

  16. Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts

    Accesswire

  17. IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease

    Accesswire

  18. IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness

    Accesswire

  19. IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025

    Accesswire

  20. IGC Pharma, Inc. (NYSEAMERICAN:IGC) Short Interest Up 15.9% in February

    Defense World